Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Olaparib is named as an intervention in 42 current clinical trials in our USA, China, UK, India and Ireland registers. 16 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (18). The most-studied condition is Ovarian Cancer.

Olaparib also has an approved-drug profile on this site (FDA label data): Lynparza (Olaparib) →

Trials by status

Recruiting1638%
Not yet open25%
Active, closed2457%

Trials by phase

Phase 31536%
Phase 21126%
Phase 1717%
Phase 1/2614%
Phase 425%
Phase 2/312%

Clinical trials of Olaparib

42 trials

Study	Phase	Status	Lead sponsor	Registers
Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer NCT07695259 · ClinicalTrials.gov ↗ · Elderly Females, HER2 + Breast Cancer, Neoadjuvant Therapy	Phase 4	Recruiting	Wen-Ming Cao	China
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) NCT03486873 · Solid Tumors, Hematologic Malignancies	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer NCT06915025 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer	Phase 3	Recruiting	Imunon	USA
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · ClinicalTrials.gov ↗ · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer NCT06686030 · ClinicalTrials.gov ↗ · Platinum-sensitive Ovarian Cancer	Phase 2	Recruiting	Akeso	China
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion NCT06739395 · ClinicalTrials.gov ↗ · Solid Tumor, Precision Medicine	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies NCT07024784 · ClinicalTrials.gov ↗ · Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer	Phase 2	Recruiting	AbbVie	USA
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) NCT05898399 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1/2	Recruiting	Artios Pharma Ltd	USA
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC NCT06217757 · ClinicalTrials.gov ↗ · Lung Cancer, Extensive-stage Small-cell Lung Cancer	Phase 1/2	Recruiting	Sichuan University	China
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Castration-Resistant	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors NCT06525298 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency	Phase 1/2	Recruiting	Eisbach Bio GmbH	USA
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Exelixis	USA
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors NCT06545942 · Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer	Phase 1	Recruiting	MOMA Therapeutics	UK, USA
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors NCT06686745 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	Jiangsu Simcere Pharmaceutical Co., Ltd.	China
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer NCT07652242 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC)	Phase 1	Recruiting	Immunomic Therapeutics, Inc.	USA
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer NCT07641855 · ClinicalTrials.gov ↗ · Castration-resistant Prostate Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd.	China
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer NCT07005583 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC)	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations NCT05457257 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer	Phase 4	Active, closed	AstraZeneca	China
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. NCT01844986 · ClinicalTrials.gov ↗ · Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV	Phase 3	Active, closed	AstraZeneca	UK, USA, China
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy NCT01874353 · ClinicalTrials.gov ↗ · Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer NCT02032823 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer NCT03732820 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients NCT03737643 · ClinicalTrials.gov ↗ · Advanced Ovarian Cancer	Phase 3	Active, closed	AstraZeneca	USA, China
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer NCT04269200 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	AstraZeneca	USA, India, China
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · ClinicalTrials.gov ↗ · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib NCT04421963 · ClinicalTrials.gov ↗ · Ovarian Cancer, Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) NCT04624204 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
D9319C00001- 1L OC Mono Global RCT NCT04884360 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Active, closed	AstraZeneca	India, China
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) NCT05171816 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer	Phase 3	Active, closed	AstraZeneca	China
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer NCT06112379 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer NCT01081951 · Ovarian Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy NCT03334617 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) NCT03459846 · Urinary Bladder Neoplasms	Phase 2	Active, closed	AstraZeneca	USA
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) NCT03742895 · Advanced Solid Neoplasms	Phase 2	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) NCT03775486 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer NSCLC	Phase 2	Active, closed	AstraZeneca	UK, USA, India
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors NCT04931342 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. NCT02734004 · ClinicalTrials.gov ↗ · Ovarian, Breast, SCLC	Phase 1/2	Active, closed	AstraZeneca	UK, USA
Study of LP-184 in Patients With Advanced Solid Tumors NCT05933265 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, GBM	Phase 1/2	Active, closed	Lantern Pharma Inc.	USA
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents NCT02264678 · ClinicalTrials.gov ↗ · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer	Phase 1	Active, closed	AstraZeneca	UK, USA
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer NCT02546661 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer	Phase 1	Active, closed	AstraZeneca	UK, USA
Study of INCB123667 in Subjects With Advanced Solid Tumors NCT05238922 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1	Active, closed	Incyte Corporation	UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Olaparib

57 conditions

Ovarian Cancer5Advanced Solid Tumor5Breast Cancer4Metastatic Solid Tumor3Metastatic Castration-resistant Prostate Cancer3Solid Tumors2Advanced Ovarian Cancer2Breast Neoplasms2Fallopian Tube Cancer2Hematologic Malignancies1Advanced Solid Neoplasms1Prostatic Neoplasms, Castration-Resistant1

All 57 conditions

Condition (as registered)	Trials
Ovarian Cancer	5
Advanced Solid Tumor	5
Breast Cancer	4
Metastatic Solid Tumor	3
Metastatic Castration-resistant Prostate Cancer	3
Solid Tumors	2
Advanced Ovarian Cancer	2
Breast Neoplasms	2
Fallopian Tube Cancer	2
Hematologic Malignancies	1
Advanced Solid Neoplasms	1
Prostatic Neoplasms, Castration-Resistant	1
Prostate Cancer	1
Pancreas Cancer	1
Non-small Cell Lung Cancer NSCLC	1
Newly Diagnosed	1
FIGO Stage III-IV	1
BRCA Mutation	1
Small Cell Lung Cancer	1
Triple Negative Breast Neoplasms	1
HR Low-Positive/HER2-Negative Breast Neoplasms	1
Platinum Sensitive	1
BRCA Mutated	1
Relapsed Ovarian Cancer	1
Following Complete or Partial Response to Platinum Based Chemotherapy	1
Lung Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
Muscle Invasive Bladder Cancer	1
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer	1
Ovarian	1
Breast	1
SCLC	1
Gastric Cancers	1
Urinary Bladder Neoplasms	1
Endometrial Neoplasms	1
Homologous Recombination Deficiency	1
HRR Deficiency	1
Gynecologic Cancers	1
Platinum-Sensitive Ovarian Cancer	1
Primary Peritoneal Cancer (PSOC)	1
GBM	1
TNBC - Triple-Negative Breast Cancer	1
Epithelial Ovarian Cancer	1
Primary Peritoneal Carcinoma	1
Non-Small Cell Lung Cancer	1
Triple Negative Breast Cancer (TNBC)	1
Advanced Solid Tumors	1
Castration-resistant Prostate Cancer	1
Solid Tumor	1
Precision Medicine	1
Triple-Negative Breast Cancer (TNBC)	1
Platinum-sensitive Ovarian Cancer	1
Lung Cancer	1
Extensive-stage Small-cell Lung Cancer	1
Elderly Females	1
HER2 + Breast Cancer	1
Neoadjuvant Therapy	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	32	11
Clinical trials in China	22	8
Clinical trials in UK	20	4
Clinical trials in India	5	1
Clinical trials in Ireland	3	2

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Olaparib trials

How many clinical trials are testing Olaparib?

42 current trials in our USA, China, UK, India and Ireland registers name Olaparib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Olaparib trials recruiting patients?

Yes. 16 of the 42 trials are recruiting: 11 with sites in USA, 8 with sites in China, 4 with sites in UK, 1 with sites in India and 2 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Olaparib clinical trials?

AstraZeneca (18), Merck Sharp & Dohme LLC (7), MOMA Therapeutics (1) and Hoffmann-La Roche (1), among 19 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Olaparib works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Olaparib works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Olaparib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Olaparib clinical trials